Vogenx initiates Phase 2b EMERGE trial of mizagliflozin for post-bariatric hypoglycemia
The company reported third-quarter 2026 results, with the trial underway and $82.1 million in cash after its August IPO.
SEC filing
3 stories
The company reported third-quarter 2026 results, with the trial underway and $82.1 million in cash after its August IPO.
SEC filing
Gorman will resign from the Vogenx board effective October 12, 2026 as he moves into the newly created commercial role.
SEC filing
The clinical-stage company named the former PA Consulting chief executive as an independent director and audit committee chair, effective September 21, 2026.
SEC filing